- Home
- » Tags
- » Oseltamivir
Top View
- FDA Update on the H1N1 Flu Vaccine and Antiviral Medications
- Xofluza, INN-Baloxavir Marboxil
- Peramivir Fact Sheet for Health Care Providers
- The Efficacy and Safety of Antivirus Drugs for COVID-19: a Systematic Review Muhammad Ardi Munir*1, Hendra Kuganda2, Amirah Basry3
- NEW ZEALAND DATA SHEET Tamiflu (Oseltamivir)
- Antiviral Therapy and Prophylaxis for Influenza in Children Committee on Infectious Diseases Pediatrics 2007;119;852 DOI: 10.1542/Peds.2007-0224
- Prescribing Information for TAMIFLU
- Tamiflu (Oseltamivir Phosphate)
- Peramivir Is an Intravenous Neuraminidase Inhibitor
- Uses and Administration Adverse Effects Profile Profile Profile Uses
- Viral Infections
- In Vitro Combinations of Baloxavir Acid and Other Inhibitors Against Seasonal Influenza a Viruses
- Interferon Lambda Delays the Emergence of Influenza Virus
- Synergistic Interferon Alpha-Based Drug Combinations Inhibit SARS
- Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives
- Use of Antivirals for Treatment and Prophylaxis of Influenza in Nsw Hospitals and Residential Care Facilities
- Oseltamivir Phosphate) (Oseltamivir Phosphate) Capsules, for Oral Use for Oral Suspension
- Treatment Profiles and Clinical Outcomes of Covid-19 Patients at Private Hospital in Jakarta
- Amantadine, Oseltamivir and Zanamivir for Influenza Treatment
- TAMIFLU Safely and Effectively
- List Item Questions and Answers on the Review of Centrally Authorised
- Antiviral Therapy and Prophylaxis for Influenza in Children Committee on Infectious Diseases Pediatrics 2007;119;852 DOI: 10.1542/Peds.2007-0224
- Antivirals Targeting the Surface Glycoproteins of Influenza Virus
- Pandemic H1N1 'Swine Flu'
- Tamiflu, INN-Oseltamivir Phosphate
- Antivirals, Influenza
- HHS Pandemic Influenza Plan
- Re , Amantadine (Review) and View
- Recommendations for Treatment & Prophylaxis of Influenza for Adults
- Reference ID: 4472011
- Review Laninamivir and Its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
- Assessment of Adverse Events Related to Anti-Influenza Neuraminidase
- Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
- Virus Susceptibility and Clinical Effectiveness of Anti-Influenza Drugs
- Epistatic Interactions Between Neuraminidase Mutations Facilitated the Emergence of the Oseltamivir-Resistant H1N1 Influenza
- Clinical Trials on Drug Repositioning for COVID-19 Treatment
- Oseltamivir: Drug Information Special Alerts Brand Names
- 2013 March (127): Treatment Guidelines
- TAMIFLU (Oseltamivir Phosphate)
- OSELTAMIVIR.Pdf
- (H1N1) 2009 and Other Influenza Viruses
- XOFLUZA (Baloxavir Marboxil) Is an Antiviral PA Endonuclease Inhibitor
- COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical
- Antiviral Medications for Seasonal Influenza: Information for Health Care Providers, 2019
- H1N1) Outbreak Tamiflu (Oseltamivir) Relenza (Zanamivir
- Assessment of Evidence for COVID-19-Related Treatments
- Influenza Antiviral Medications: Summary for Clinicians
- Tamiflu, INN-Oseltamivir
- H5N1 Avian Influenza: Timeline of Major Events 25 January 2012
- Recommendations for Prevention and Control of Influenza in Children, 2020–2021
- Antiviral Medications to Treat/Prevent Influenza (The Flu) During Pregnancy
- Prescribing Information
- Clinical Use of Approved Influenza Antivirals
- NDA 214410/Original 1 & Ndas 210854/S-04, 10; Xofluza
- Tamiflu® Treatment and Prophylaxis Information Per CDC Recommendations
- Influenza: Questions and Answers Information About the Disease and Vaccines
- CDC Advisory 00279
- Successful Treatment with Baloxavir Marboxil of a Patient with Peramivir
- A Review of the Safety of Favipiravir – a Potential Treatment in the COVID-19